Athena Athena

X
[{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$10.0 million","newsHeadline":"CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology's 1st Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 and OPDIVO\u00ae Combo in Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"CG Oncology Closes $47 Million Series D Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Doses First Patient in Oncolytic Immunotherapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Participation in Global Phase III Clinical Trial For CG0070, a Drug for Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Gu\u00e9rin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$437.0 million","upfrontCash":"Undisclosed","newsHeadline":"CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by CG Oncology

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The company intends to use the net proceeds to fund the research and development of Cretostimogene grenadenorepvec

            Lead Product(s): Cretostimogene Grenadenorepvec

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Morgan Stanley

            Deal Size: $437.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering January 30, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will support the clinical programs in bladder cancer towards FDA approval including a Phase 3 study for CG0070 (cretostimogene grenadenorepvec) as a potential treatment for high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin.

            Lead Product(s): Cretostimogene Grenadenorepvec

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Foresite Capital

            Deal Size: $105.0 million Upfront Cash: Undisclosed

            Deal Type: Financing August 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.

            Lead Product(s): Cretostimogene Grenadenorepvec

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG).

            Lead Product(s): Cretostimogene Grenadenorepvec,Pembrolizumab,Dodecyl Maltoside

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.

            Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication.

            Lead Product(s): Engineered Oncolytic Adenovirus,Pembrolizumab

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.

            Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.

            Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The interim Phase 2 results showed that combination of CG0070 and pembrolizumab was well tolerated with encouraging early efficacy data in 18 patients, with 89% of patients evaluable for efficacy have achieved complete response at initial 3-month timepoint.

            Lead Product(s): CG0070,Pembrolizumab

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The preliminary Phase 2 results showed that a combination of CG0070 and pembrolizumab was well tolerated with encouraging early efficacy data in 9 patients. In advanced clinical trials, CG0070 is a safe and efficacious agent in NMIBC following BCG failure.

            Lead Product(s): CG0070,Pembrolizumab

            Therapeutic Area: Oncology Product Name: CG0070

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY